Starling Oncology, Inc. (STLN)
Healthcare • Medical Care Facilities
StockNasdaqCMUnited StatesUS68236X1000
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Starling Oncology, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 10:43. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Mar 2027 16:00 | -0.02 | — | — | Upcoming |
| 05 Nov 2026 16:00 | -0.05 | -0.13 | -160.0% | Miss |
| 06 Aug 2026 16:00 | -0.06 | -0.08 | -25.0% | Miss |
| 07 May 2026 16:00 | -0.09 | -0.02 | +77.1% | Beat |
| 12 Mar 2026 16:00 | -0.09 | -0.06 | +33.3% | Beat |
| 13 Nov 2025 16:00 | -0.11 | -0.14 | -23.5% | Miss |
| 13 Aug 2025 16:00 | -0.12 | -0.15 | -25.0% | Miss |
| 13 Aug 2024 16:00 | -0.10 | -0.14 | -35.6% | Miss |
| 14 May 2024 16:00 | -0.12 | -0.19 | -58.3% | Miss |
| 26 Mar 2024 20:00 | -0.11 | -0.16 | -47.9% | Miss |
| 08 Nov 2023 16:00 | -0.13 | 0.06 | +142.3% | Beat |
| 08 Aug 2023 16:00 | -0.17 | -0.19 | -12.2% | Miss |
| 09 Mar 2023 16:00 | -0.20 | -0.22 | -11.9% | Miss |
| 09 Nov 2022 16:00 | -0.18 | -0.88 | -390.7% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 502.7M | +27.8% | -60.6M | -12.1% | -0.54 | +23.9% | -27.8M |
| 2024 | 393.4M | +21.3% | -64.7M | -16.4% | -0.71 | +22.8% | -30.3M |
| 2023 | 324.2M | +28.4% | -83.1M | -25.6% | -0.92 | -360.0% | -40.9M |
| 2022 | 252.5M | — | 152K | 0.1% | -0.20 | — | -67.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 4.10 | 4.24 | 3.67 | 3.75 | -10.71% | 6,548,500 | |
| 11 Nov 2026 | 4.81 | 4.81 | 4.16 | 4.20 | -3.23% | 2,977,900 | |
| 10 Nov 2026 | 3.97 | 4.44 | 3.97 | 4.34 | +8.50% | 6,453,900 | |
| 09 Nov 2026 | 3.98 | 4.53 | 3.50 | 4.00 | +10.50% | 8,837,700 | |
| 06 Nov 2026 | 6.06 | 6.43 | 3.35 | 3.62 | -45.97% | 23,917,500 | |
| 05 Nov 2026 | 6.88 | 7.02 | 6.56 | 6.70 | -3.46% | 2,081,100 | |
| 04 Nov 2026 | 6.44 | 7.04 | 6.41 | 6.94 | +9.46% | 1,688,100 | |
| 03 Nov 2026 | 6.25 | 6.37 | 6.19 | 6.34 | +1.44% | 1,011,800 | |
| 02 Nov 2026 | 6.53 | 6.53 | 6.23 | 6.25 | -4.29% | 1,460,700 | |
| 30 Oct 2026 | 6.49 | 6.69 | 6.35 | 6.53 | -1.80% | 1,422,300 | |
| 1,249 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- BTIG Reiterates Buy on Starling Oncology, Maintains $10 Price Target (opens in a new tab) Benzinga · 09 Nov 2026 06:12
- Lake Street Maintains Buy on Starling Oncology, Lowers Price Target to $8 (opens in a new tab) Benzinga · 06 Nov 2026 21:27
- Oncology Institute Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 06 Nov 2026 14:14
- B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10 (opens in a new tab) Benzinga · 06 Nov 2026 12:03
- Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 06 Nov 2026 11:54
- BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10 (opens in a new tab) Benzinga · 06 Nov 2026 06:37
- Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 05 Nov 2026 21:45
- Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance (opens in a new tab) 05 Nov 2026 21:06
- Starling Oncology Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 05 Nov 2026 18:44
- Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est (opens in a new tab) Benzinga · 05 Nov 2026 18:25
- Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate (opens in a new tab) Benzinga · 05 Nov 2026 17:18
- Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views (opens in a new tab) Simply Wall St. · 16 Oct 2026 00:22
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 4.20 USD
- Market cap
- 382.5M
- Exchange
- NasdaqCM
- Country
- United States
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 10.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 15.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -3.2× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Price / book | -11.48× | Weak | 3.5× |
| Price / sales | 0.69× | Good | 3.33× |
| EV / EBITDA | -34.3× | Weak | 11.19× |
| Free cash flow yield | 6.9% | Good | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 16.7% | Weak | 54.9% |
| Operating margin | -3.4% | Weak | 5.8% |
| Net margin | -5.7% | Weak | 1.2% |
| Return on assets | -7.5% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 25.8% | Good | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -6.6× | Good | 0.4× |
| Interest cover | -3.2× | Weak | 2.17× |
| Current ratio | 1.11× | Fair | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow STLN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.